European Medicines Agency recommends suspension of all buflomedil-containing medicines

Benefits of vasoactive agents do not outweigh risks of serious cardiological and neurological side effects

 

London, UK (November 17, 2011) – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded a review of the safety and efficacy of buflomedil, saying that the risks of these medicines, particularly the risks of severe cardiological and neurological adverse reactions, are greater than their limited benefits in the treatment of patients with chronic peripheral arterial occlusive disease (PAOD). The Committee therefore recommended that the marketing authorisations of all buflomedil-containing medicines be suspended in all European Union (EU) Member States where they are currently authorised.

 

Doctors should stop using buflomedil and consider alternative treatment options, including managing underlying health problems which can increase the risk of PAOD, such as diabetes, high blood pressure as well as smoking.

 

Patients using buflomedil-containing medicines should make an appointment with their doctor at a convenient time to discuss their ongoing treatment.

 

Buflomedil, a vasoactive agent, is used to treat the symptoms of peripheral arterial occlusive disease (PAOD). This is a condition where the body’s large arteries become obstructed causing symptoms such as pain and weakness, particularly in the legs. Buflomedil is used in patients with stage II PAOD, who experience severe pain when walking even relatively short distances.

 

The review of buflomedil was initiated following the suspension of the marketing authorisation in France by the French regulatory authority in February 2011.

 

The CHMP considered all available data on the benefits and risks of buflomedil, including the benefit-risk assessment carried out by France, data from clinical studies, post-marketing surveillance and published literature, as well as from poison control centres in the EU.

 

Following review of these data the Committee concluded that:

 

  • there was a risk of serious neurological and cardiac side effects in patients taking buflomedil under normal conditions of use and that risk minimisation measures such as changes to the packaging of the medicine, recommendations on adjusting the dose for patients with kidney problems and restrictions on the medicines’ use in certain patients had not been able to reduce these risks to an acceptable level.
  • due to the narrow therapeutic index (i.e. the small difference between buflomedil’s therapeutic dose and its toxic dose) there was a significant risk of adverse events, particularly in elderly patients and in patients with certain conditions such as kidney problems, which are common in PAOD.

 

  • data in support of the benefit of the medicine for patients were limited and of poor quality.

 

The Committee was therefore of the opinion that the benefits of buflomedil-containing medicines do no longer outweigh their risks, and recommended that marketing of these medicines should be suspended throughout the EU.

 

 

Notes

 

  • Buflomedil-containing medicines have been authorised in the EU since the 1970s via national procedures. Buflomedil is authorised in the form of tablets, an oral solution or a solution for injection in Austria, Belgium, Cyprus, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Poland, Portugal and Spain under the invented name Loftyl and other trade names.

 

  • The review was carried out under Article 107 of Directive 2001/83/EC. This type of procedure is triggered when a Member State varies, suspends or revokes the marketing authorisation for a medicine in its territory because of a safety issue.

 

  • The CHMP’s recommendation will be sent to the European Commission for the adoption of a decision.

 

  • All other opinions and documents adopted by the CHMP at their November 2011 plenary meeting will be published on Friday, 18 November 2011 at 12.00 noon UK time on a dedicated web page.

 

 


European Medicines Agency (EMA), 17.11.2011 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung